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Abstract
Background: Mannose-binding Lectin protein (MBL) has been suggested to be relevant in the defence against infections in
immunosuppressed individuals. In a Swedish adult cohort immunosuppressed from both the underlying disease and from
iatrogenic treatments for their underlying disease we investigated the role of MBL in susceptibility to infection.
Methods: In this cross sectional, prospective study, blood samples obtained from 96 neutropaenic febrile episodes,
representing 82 individuals were analysed for single nucleotide polymorphism (SNP) in the MBL2 gene. Concurrent
measurement of plasma MBL protein concentrations was also performed for observation of acute response during febrile
episodes.
Findings: No association was observed between MBL2 genotype or plasma MBL concentrations, and the type or frequency
of infection. Adding to the literature, we found no evidence that viral infections or co-infections with virus and bacteria
would be predisposed by MBL deficiency. We further saw no correlation between MBL2 genotype and the risk of fever.
However, fever duration in febrile neutropaenic episodes was negatively associated with MBL2 SNP mutations (p,0.05).
Patients with MBL2 SNP mutations presented a median febrile duration of 1.8 days compared with 3 days amongst patients
with wildtype MBL2 genotype.
Interpretation: We found no clear association between infection, or infection type to MBL2 genotypes or plasma MBL
concentration, and add to the reports casting doubts on the benefit of recombinant MBL replacement therapy use during
iatrogenic neutropaenia.
Citation: Wong M, O¨hrmalm L, Broliden K, Aust C, Hibberd M, et al. (2012) Mannose-Binding Lectin 2 Polymorphisms Do Not Influence Frequency or Type of
Infection in Adults with Chemotherapy Induced Neutropaenia. PLoS ONE 7(2): e30819. doi:10.1371/journal.pone.0030819
Editor: Silke Appel, University of Bergen, Norway
Received July 29, 2011; Accepted December 21, 2011; Published February 17, 2012
Copyright:  2012 Wong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Swedish society of Medicine, Stockholm county council, Swedish childhood cancer foundation and the
Groschinsky foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: michelle.wong@ki.se
Introduction
Mannose-Binding Lectin protein (MBL) is a member of the
collectin family of proteins which function as pattern recognition
molecules in the innate immune system. MBL recognises and
binds to sugar groups present on a wide range of microorganism
and plays a significant role as a first line defence against invading
pathogens by triggering the complement pathway using MBL-
associated serine proteases and possibly functioning as a toll-like
receptor co-receptor [1,2]. Single nucleotide polymorphisms
(SNPs) located within the promoter region and exon 1 of MBL2
have been correlated with MBL serum levels [3]. Within exon 1,
the wildtype variant is termed ‘A’ and relevant SNP mutations at
positions +154 (D variant), +161 (B variant) and +170 (C variant)
are collectively denoted by ‘O’. In the promoter regions, three
relevant SNP loci have been identified at positions -619 (H/L),
2290 (X/Y) and266(P/Q). In the presence of wildtype ‘A’, HYP,
LYP and LXP have been associated with high, intermediate and
low MBL levels respectively [3,4]. The combinatorial effect of
SNPs in the promoter and coding region of MBL2 results in
variations in MBL concentrations [3,4]. Whilst constitutional
MBL deficiency is unlikely to be clinically relevant in healthy
adults [5], this may not be the case in patients with myelosup-
pression from chemotherapy. Antineoplastic chemotherapy pri-
marily affects the cellular components of the adaptive and innate
immune system rendering acellular components of the innate
immune system such as MBL potentially important in the role of
microbial defense.
Infection episodes are common in patients after induction of
chemotherapy during the subsequent neutropaenic phase and
account for significant mortality [6]. In 2001, Neth et al. reported
a significant increase in the duration and frequency of chemo-
therapy-induced neutropaenic febrile episodes amongst children
with serum MBL deficiency [7]. Subsequent studies in adult
patients treated with antineoplastic chemotherapy have yielded
conflicting conclusions and metanalyses of data from adult patients
are lacking. Low plasma protein levels of MBL has been associated
to serious infections related to chemotherapy by Peterslund et al.,
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and Vekemans et al. conclude that while MBL deficiency does not
predispose to more frequent or prolonged febrile episodes during
myelosuppressive therapy, an association with more severe
infections exist [8,9]. In contrast, Bergmann et al. and Kilpatrick
et al. dismiss any strong relationship between low MBL levels and
febrile neutropaenia [10,11]. Furthermore, Lopez et al. and
Klostergaard et al. did not find an association between MBL2
genotype and number of infectious episodes following chemother-
apy against follicular lymphoma and occurrence of septicaemia,
respectively [12,13].
Comparisons between previous studies are inherently compli-
cated by different distribution of haematological malignancies in
the cohorts, different therapies administered and measurement of
either serum MBL levels or MBL2 genotype and induction of
MBL by inflammation could introduce a temporal sampling bias
in studies relying on only protein measurement. Furthermore,
association to infection aetiology, apart from unspecified bacter-
aemia, has yet not been performed. In addition to earlier reports
on MBL binding to viral glycoproteins [14,15], MBL has recently
been shown to have protective effects against Ebola virus in an in
vivo murine model [16].
As recombinant human MBL has been put through phase I
studies [17] based on the suggestion that it is able to decrease
infection-related complications in MBL deficient patients with
iatrogenic neutropaenia, further study of the role of MBL and
other innate constituents in granulocytopaenia are warranted.
Here, we sought to study the association of plasma MBL levels and
MBL2 coding and promoter region genotypes to infection, type of
infection and, febrile episodes in adults with chemotherapy
induced neutropaenia.
Materials and Methods
Study population
The study was approved by The Regional Ethical Review
Board in Stockholm, permit numbers 2007/1213-31/4 and 2008/
1300-32.
During a 26 month period (January 2008 to February 2010),
adult patients with haematological disorders at the Karolinska
University Hospital, Stockholm were, after informed written
consent, included in a cross sectional study where the inclusion
criterion was chemotherapy-induced neutropaenia (absolute
neutrophile count #500/mm3). Patients that developed fever
(auricular temperature.38?0uC twice within an hour or$38?5uC
at one occasion) were sampled within 72 hours from fever onset,
whereas patients without fever were sampled upon routine medical
appointments during the neutropaenia episode. Whole blood was
collected in EDTA-tubes; plasma and blood clots were stored
separately at280uC until use for MBL measurement and genomic
DNA extraction, respectively. Additional blood and nasal
pharyngeal aspirates (NPA) samples were collected for microbio-
logical testing. C-reactive protein (CRP) concentrations were
measured as a clinical routine on the sampling day and acquired
from the medical records. Medical records were retrospectively
acquired for all included patients. Data was collected from
diagnosis of the haematological disorder, through all neutropaenic
episodes and ceased upon the patient’s recovery, demise or study
closure (June 2010), whichever was earlier. Episodes associated
with patients migrating into the Stockholm area after initiation of
treatment had been excluded from the retrospective, patient-
centric analysis but still included in episode-centric analysis
pertaining to MBL2 genotypes and the corresponding plasma
protein levels. Patients that underwent liver transplants were
excluded since MBL is produced in the liver and genotypes may
vary between the donor and recipient. In the same manner,
patients that had undergone allogeneic haematopoietic stem cell
transplantation (HSCT) were also excluded.
MBL2 genotyping
Six SNPs, rs11003125 (L/H allele), rs7096206 (X/Y allele),
rs7095891 (P/Q allele), rs5030737 (D variant), rs1800450 (B
variant) and rs1800451 (C variant) were investigated. DNA was
extracted from the blood clots with QIAamp blood DNA midi kit
(Qiagen) according to the manufacturer’s protocol and SNP alleles
were subsequently determined by sequencing. A nested PCR
protocol was designed to selectively amplify the promoter and
exon 1 regions of the MBL2 gene. A pair of primers, MBL2_Out_F
-59- TTGCCAGTGGTTTTTGACTC-39 and MBL2_Out_R-59-
TGCCAGAGAATGAGAGCTGA -39 was first used to amplify a
1079 bp segment of the MBL2 gene, including the six SNP loci.
PCR amplification was performed in a 50 ml reaction consisting
5 ml DNA template, 16 pfu PCR buffer, 200 mM dNTP, 400 nM
of each primer and 1?5 U pfu DNA polymerase (Promega
Corporation). Amplification was carried out with an initial
denaturation at 95uC for 2 minutes, followed by 35 cycles of
95uC for 1 minute, 65uC for 1 minute and 72uC for 1 minute, and
a final extension at 72uC for 7 minutes. PCR products from the
above reaction were then used for further amplification prior to
sequencing. Two pairs of primers were designed to flank the SNPs
in exon 1 and the promoter regions respectively. Primers for the
promoter region are MBL2_PROMOTER_F-59-TTCCTGCCA-
GAAAGTAGAGAGG-39 and MBL2_PROMOTER_R-59- GG-
ATCCTAAGGAGGGGTTCA-39 whilst primers for the exon 1
region are MBL2_EXON1_F-59- AGTCACGCAGTGTCACA-
AGG-39 and MBL2_EXON1_R-59- CAGGCAGTTTCCTCTG-
GAAG-39. PCR amplification mix for the promoter region
consists of 1 ml PCR product from the Out primer, 16 pfu PCR
buffer, 200 mM dNTP, 400 nM of each primer, 1?5 U pfu DNA
polymerase and water to a final volume of 50 ml. PCR cycling
condition begins with an initial denaturation at 95uC for
2 minutes, followed by 35 cycles of 95uC for 1 minute, 55uC for
1 minute and 72uC for 1 minute, and a final extension step at
72uC for 7 minutes. For the exon 1 region, the PCR amplification
mix consists of 1 ml PCR product from the out primer, 16 pfu
PCR buffer, 200 mM dNTP, 800 nM of each primer, 1.5 U pfu
DNA polymerase and water to a final volume of 50 ml. PCR
cycling condition begins with an initial denaturation at 95uC for
2 minutes, followed by 35 cycles of 95uC for 1 minute, 65uC for
1 minute and 72uC for 1 minute, and a final extension step at
72uC for 7 minutes. PCR products from promoter and exon 1
region were then purified with QIAquick gel extraction kit
(Qiagen) after separation with 1.5% agarose and sequenced with
ABI3730XL after ABI BigDye Terminator v3.1 (Applied Biosys-
tems) reactions. SNP alleles were then determined according to the
sequencing chromatograms.
MBL plasma concentrations
MBL plasma concentrations were measured with a commer-
cially available MBL oligomer ELISA kit (Bioporto Diagnostics).
The dynamic range for the assay was 0.5 mg/L 240 mg/L and
plasma samples were diluted 100 to 1000 times for measurement
within this range.
Microbiology
Bacteria were cultured from blood and PCR viral diagnostics
for adenovirus, Epstein - Barr virus and cytomegalovirus were
performed, as per normal clinical routine, by the local clinical
microbiology laboratory, Karolinska University Hospital. Viral
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diagnostics for BK polyomavirus from blood samples and,
respiratory viruses from NPA samples were however, based on
PCR methods described in previous studies [18,19,20,21,22,
23,24] and Ohrmalm et al [25].
Statistical analysis
Statistical analyses were made with the Prism suite (Graphpad
Inc). Fisher’s exact test and Mann-Whitney were used for
investigating the patients’ general characteristics while the chi-
squared test was used for determining congruence of SNP
prevalence with a reference Danish population and determining
Hardy-weinberg equilibrium. Kruskal-wallis test was used for all
other analyses where comparison of continuous data for 3 groups
or more were required.
Results
A total of 109 episodes of fever during neutropaenia were
sampled and 13 were excluded due to insufficient genomic
material for genotyping. Thirty-three afebrile neutropaenic
episodes were also included as controls. This amounted to 82
febrile neutropaenic patients and 26 afebrile neutropaenic patients
(Table 1 and 2). The majority of patients were treated for acute
leukaemias and none were diagnosed with invasive fungal
infections. Genotype frequencies for the six SNPs investigated,
and seven common haplotypes were in Hardy-weinberg equilib-
rium (Table 3) and were congruent with previous studies
conducted amongst healthy Danes [3,4]. MBL concentrations in
our study were also similar to those observed in another
chemotherapy-induced neutropaenic cohort [10]. In line with
previous studies, mutations in the MBL2 coding region corre-
sponded to a reduction (p,0.001) of plasma MBL concentrations
(Table 2). Amongst A/A individuals, mutations in the H/L SNP
locus did not result in any significant change in MBL
concentrations. X/Y locus mutations correlated with significantly
(p,0?001) reduced MBL concentrations and the much less studied
P/Q locus contributed to significant (p=0?0149) concentration
reduction as well. Hence, in the presence of functional MBL
protein, the impact of the promoter and P/Q SNPs increase in the
following order; H/L,P/Q,X/Y. With A/O individuals, the P/
Q SNP did not have significant impact on MBL concentrations.
Instead, mutations in the H/L and X/Y SNP loci were able to
significantly (p,0?001 and p=0?006, respectively) reduce MBL
concentrations. The number of O/O individuals included in this
study was too few for further analysis. Taking into account the
correlation of X/Y allele in both the A/A and A/O individuals,
additional classification into XA/XA, XA/YA, YA/YA, XA/YO,
YA/YO and YO/YO was performed and the corresponding
median MBL concentrations differed significantly (p,0.0001)
(Fig. 1b).
As the promoter SNP, X/Y played a secondary role in relation
to the coding region SNPs in correspondence to MBL concentra-
tions all further analyses were limited to mutations in the coding
region and the X/Y locus only. All blood samples were collected
within 72 hours of fever onset and time-dependent differences in
MBL concentrations was not observed within this time-frame
(p=0?747). Underlying diseases, treatment regime and absolute
neutrophile counts, were investigated and shown not to be
confounding factors to the MBL concentrations (Table 1, 2).
Based on genotype, individuals were classified into 2 groups,
wildtype (A/A) and mutants (A/O, O/O). Mutations in the MBL2
coding region could result in an unstable protein oligomer
consequently, episodes arising from A/A individuals were used
for analysis on microbiological findings. In an episode-centric
analysis, MBL protein concentrations from A/A individuals with
febrile episodes did not vary with bacterial or viral findings, co-
occurrence of bacteria and virus or the absence of microbiological
findings (Fig. 2a). Furthermore, no association was observed
between MBL concentration and fever presentation, as shown by
comparison between febrile and afebrile neutropaenic episodes.
For comparison, CRP concentrations differed significantly be-
tween neutropaenic patients with and without fever (p,0?001)
Table 1. General characteristics of febrile and afebrile neutropaenic episodes.
Fever Without fever
MBL2 coding regions
MBL2 coding
regions
A/A A/O+O/O A/A A/O+O/O
(n=55) (n=41) p-value OR (95%CI) (n= 20) (n=13) p-value OR (95%CI)
Days to febrile episode, median (IQR) 2 (1.0–5.25) 3 (1.0–4.25) 0.94 - - - - -
Underlying disease
Acute Leukaemia (%) 31 (57.4) 23 (50.0) 0.55 1.35 (0.61–2.97) 10 (47.6) 3 (20) 0.159 3.64 (0.789–16.76)
Chronic Lymphocytic Leukaemia (CLL) (%) 1 (1.9) 2 (4.3) 0 2 (13.3) - -
Hodgkin Lymphoma (%) 1 (1.9) 2 (4.3) 3 (14.3) 2 (13.3) - -
Myeloma (%) 8 (14.8) 5 (10.9) 0.77 1.43 (0.43–4.71) 0 1 (6.7) - -
Non-Hodgkin’s lymphoma (NHL)(%) 13 (24.1) 13 (28.3) 0.65 0.80 (0.33–1.97) 8 (30.1) 6 (40.0) 1.00 0.92 (0.237–3.589)
Other haematological malignancy (%) 0 (0.0) 1 (2.2) 0 1 (6.7) - -
Treatment type
Antineoplastic chemotherapy (%) 52 (96.3) 42 (91.3) 1.00 1.24 (0.24–6.46) 19 (90.5) 14 (93.3) 1.00 0.68 (0.06–8.25)
Steroids (%) 9 (16.7) 13 (28.3) 0.15 0.48 (0.18–1.26) 3 (14.3) 2 (13.3) 1.00 1.08 (0.16–7.44)
Monoclonal antibodies (%) 7 (13.0) 5 (10.9) 1.00 1.17 (0.34–3.96) 2 (9.5) 1 (6.6) 1.00 1.47 (0.12–17.92)
Cyclosporine A or takrolimus (%) 0 (0.0) 1 (2.2) 1 (4.8) 0 (0.0) 1.00 2.27 (0.09–59.6)
doi:10.1371/journal.pone.0030819.t001
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(Fig. 2b). Amongst episodes with virus findings, no significant
differences in MBL concentrations were observed between virus
positive samples taken from blood and nasopharynx (Table 4). In
blood, the most common virus finding was BK polyomavirus and
cytomegalovirus while in the NPA samples, the most common
finding was human rhinovirus. Corresponding analyses with XA/
XA, XA/YA, YA/YA, XA/YO, YA/YO and YO/YO genotypes
did not yield any correlation either.
Patient-centric analysis was used for investigations on clinical
outcome. No correlation could be observed between MBL2
genotype and the risk of fever. However, the proportional days
of fever during febrile neutropaenic episodes was weakly negatively
associated with the presence of MBL2 SNP mutations (p=0?041).
Patients with MBL2 SNP mutations (A/O an O/O) presented a
median febrile duration of 1?8 days (IQR=1?0–3?8) compared
with 3 days (IQR=2?0–4?7) amongst patients with wildtype (A/A)
MBL2 genotype (Fig. 3). Antibiotic use corresponded closely to the
manifestation of fever and the same trend was observed. Antibiotic
treatment duration in wildtype A/A individuals were longer
(p=0?018) than in individuals with MBL2 SNP mutations (A/O
and O/O), with a median of 9?0 and 7?0 days, respectively. This
association, was however, not observed with the when the X/Y
locus was included in the analysis (XA/XA, XA/YA, YA/YA,
XA/YO, YA/YO, YO/YO) (data not shown).
Discussion
Our study set out to investigate, in an episode-centric analysis,
the role of MBL as a risk factor for infection and type of infection
among adults presenting with neutropaenic febrile episodes after
undergoing chemotherapy for their underlying haematological
malignancies. We further utilised patient-centric analysis to
investigate associations between MBL2 genotype and risk of fever
in this cohort.
In the absence of Swedish genotype frequencies for the MBL2
gene, Danes were selected as a reference population for our study.
Whilst there have been other SNP loci identified for MBL2
[26,27,28], our investigations focussed on 6 SNPS that had been
previously reported to have an effect on protein concentrations
[3]. Nonetheless, we had looked at additional SNPs [27] and saw
that our cohort was homozygous for all the SNP loci except for the
rs10556764 deletion, rs34120190, rs11003124, rs7084554,
rs36014597 and rs10556764 where the frequency for the minor
allele was low and could not be included for statistical analysis.
The genotype frequencies of the MBL2 SNPs we examined
corresponded well with previous investigations of a Danish cohort,
however, median MBL concentrations observed in both the
wildtype (A/A) and mutant (A/O, O/O) individuals in our cohort
were seemingly higher than that reported on healthy Danes [3,4]
suggesting that MBL concentrations are already elevated at the
time of sampling, regardless of any ensuing infection. This finding
could derive from inflammation caused by the malignant disease
itself and has been observed in a similar cohort [10]. Indeed, MBL
has been shown to bind directly to transformed cell lines exhibiting
an aberrant glycosylation pattern [29]. The preceding chemo-
therapy cycle could also have contributed via MBL binding to
apoptotic cells and clearance of dying cells through phagocytosis
[30]. Although MBL concentrations were found to be higher than
in healthy individuals, concentrations were not significantly
different between neutropaenic patients with fever and without
fever. Furthermore, MBL concentrations between patient groups
Table 3. MBL2 genotype frequencies observed in this cohort
(n = 108).
Genotype Haplotypes
Promoter n (%)
dbSNP ID allele n (%) HYPA 64 (29.6)
rs11003125 L/L 47 (43.5) LYPA 13 (6.0)
L/H 46 (42.6) LYQA 43 (19.9)
H/H 15 (13.9) LXPA 45 (20.8)
LYPB 35 (16.2)
rs7096206 Y/Y 67 (62.0) LYQC 4 (1.9)
Y/X 34 (31.5) HYPD 12 (5.6)
X/X 7 (6.5) LYPD 0 (0.0)
rs7095891 P/P 69 (63.9)
P/Q 31 (28.7)
Q/Q 8 (7.4)
Exon 1
dbSNP ID allele n (%)
rs5030737 A/A 96 (88.9)
A/D 12 (11.1)
D/D 0 (0.0)
rs1800450 A/A 75 (69.4)
A/B 30 (27.8)
BB 3 (2.8)
rs1800451 A/A 104 (96.3)
A/C 4 (3.7)
C/C 0 (0.0)
Total A/A 63 (58.3)
A/O 39 (36.1)
O/O 6 (5.6)
doi:10.1371/journal.pone.0030819.t003
Figure 1. MBL2 XA/XA, XA/YA, YA/YA, XA/YO, YA/YO, YO/YO
genotypes with the corresponding plasma MBL concentrations
(**p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0030819.g001
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diagnosed with bacterial, viral or, bacterial and viral co-infections
did not differ significantly. In-depth analysis of MBL concentra-
tions and the location of virus findings did not offer more clarity on
the potential antiviral role of MBL in this patient cohort. This said
it is still possible that any concurrent increase in response by MBL
to infection could be obscured by elevation elicited by the
neoplasm, or massive cell-death induced by cytotoxic therapy.
Little is known regarding the kinetics of MBL secretion but Neth et
al. suggested that a peak was seen only seven days after the start of
a febrile neutropaenic episode [7]. We collected all samples within
72 hours from the start of a febrile neutropaenic episode which
might have been premature for any observation of MBL infection
kinetics between pathogen types. Nevertheless, we could not find
any association between MBL concentration and time between
fever onset and sampling. With another acute phase protein, CRP,
differences were apparent between patients that developed fever
during neutropaenia and, those that did not. Amongst the group
with fever, no difference in CRP was observed regardless of
pathogen type, in concurrence with MBL concentrations. The
latter observation is not surprising since these patients are, as an
effect of their cytopaenia, limited in their ability for IL-1 and IL-6
response. A negative correlation between CRP, IL-1 and MBL has
been observed by Aittoniemi et al. among febrile septic patients
indicating that MBL and CRP are regulated differently [31]. Arai
et al. further demonstrated in haepatoma cell lines that IL-6
stimulates MBL production while IL-1 inhibits it [32]. Taken
together, MBL elevation by infection is unlikely to impact the
association between MBL concentrations and predisposition to
infection.
Table 4. Plasma MBL concentrations in wildtype (A/A)
individuals with virus findings.
Location of virus findings
Blood Nasopharynx p-value
MBL concentrations (mg/L) (IQR)
Febrile patients n = 16 n= 8
3487
(2945–4756)
3167
(1172–6448)
0.9756
Afebrile controls n = 1 n= 1
6287 771.3 -
doi:10.1371/journal.pone.0030819.t004
Figure 3. The proportional days of fever and days of antibiotic
treatment during febrile neutropaenia episodes among A/A
(n=46) and A/O+O/O (n=41) individuals. (*p,0.05).
doi:10.1371/journal.pone.0030819.g003
Figure 2. Plasma concentrations of (A) MBL and (B) CRP, in afebrile and febrile episodes based on pathogen detected. Comparisons
were made between afebrile episodes and febrile episodes with further catergorisation based on microbiological findings. Numbers in the respective
groups are listed in Table 2 (**p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0030819.g002
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In our hands, no association was observed between MBL2
genotype or MBL concentrations and the type of infection or the
frequency of infection in chemotherapy induced neutropaenia in
adults. This is in stark contrast to a study performed by Peterslund
et al. in a similar adult cohort [8]. Vekemans et al., conclude that
MBL deficiency is associated to severe infection episodes defined
as pneumonia, septicaemia or invasive fungal infection [9]. It
could be argued that our material could lack sufficient statistical
power to detect an association to severe infection, which, in our
cohort is represented by clinically significant bacteraemia
(p=0?09). However, Klosterggard et al. focused only on this
association and found no MBL2 genotype associations to sepsis or
death by sepsis [13]. In line with our data are several reports
where no strong association between infection and MBL
deficiency were found, but meta-analyses are missing [10,11,12].
Adding to the literature, we found no evidence that viral infections
or co-infections with virus and bacteria would be predisposed by
MBL deficiency. A weak association in our material was that
mutations in the MBL2 exon 1 region recorded fewer febrile days
per febrile neutropaenic episode (p=0?04), in covariance with time
of antibiotic treatment. While this observation may be elicited by
chance itself it contradicts the findings of Neth et al. who suggested
that MBL2 mutations predisposed longer febrile duration among
children undergoing chemotherapy [7]. Interestingly, no associa-
tion of the same clinical parameters and the promoter SNP X/Y,
which had profound effect on MBL concentration, was apparent.
An earlier report on the role of MBL2 polymorphisms and
recurrent respiratory infections in children suggested that it was
the coexistence of (partial) immune defects, rather than any one
single immunological aetiologic factor that was associated to the
disease outcome [33]. We could speculate that this might
contribute to the weak associations we observe and suggest
consideration of this notion, originally suggested by Turner MW
[34], for future studies [35].
In summary, in this adult cohort we found no clear association
between infection, or infection- type to MBL2 genotypes or MBL
concentration, and add to the reports casting doubts on the benefit
of recombinant MBL replacement therapy use during iatrogenic
neutropaenia.
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